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Abstract 
Acute lymphoblastic leukemia (ALL) with 
hypereosinophilia is a rare disease, with the 
majority of reported cases being B-lineage ALL. 
Although eosinophilia is considered a reactive, non-
neoplastic epiphenomenon, it adversely affects 
patient outcomes, both in children and adults. It is a 
distinct clinical entity by World Health 
Organization (WHO) 2008 and commonly 
associated with a unique cytogenetic abnormality. 
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Identity 
Marked eosinophilia is an uncommon finding in 
ALL. It may precede the diagnosis of ALL or occur 
simultaneously at the time of diagnosis. Eosinophils 
can mask the underlying or coexisting leukemia. 
Therefore, comprehensive evaluation for 
unexplained hypereosinophilia should be carried 
out to rule out possibility of malignancy including 
ALL, even in the absence of peripheral circulating 
blasts. 
Clinics and pathology 
Epidemiology 
ALL with hypereosinophilia is reported in <1% of 
ALL cases. The disease was first described by 
Spitzer and Garson in 1973. Subsequently, over 50 
adult and pediatric cases have been documented in 
the literature (Fishel et al, 1990; Parasole et al 
2014).  The majority of the described cases have B-
cell phenotypes. In 1980, Catovscky et al reported 
two cases of T-cell ALL with eosinophilia.  ALL 
with eosinophilia cases are predominantly male 
patients, median age at presentation of 15 years 
with an age range of 2-71 years (Fishel et al, 1990; 
Wilson & Tefferi, 2005; Parasole et al, 2014). 
Clinics 
Clinical presentations may be similar to other 
patients with ALL. Whereas some patients may be 
presented with signs and symptoms 
indistinguishable from hypereosinophilic syndrome, 
and death in some patients appears to have occurred 
as a complication of eosinophilic tissue damage 
(Rezamand et al, 2013; Bomken et al, 2015). 
Eosinophilia may precede the diagnosis of leukemia 
by 1-9 months and during this period, the patients 
may present with urticarial hyperpigmented plaques 
and other non-hematological features of HES such 
as cardiomyopathy, pneumonitis, dermatitis, 
sinusitis, central nervous system or peripheral 
neuropathy (Chien et al, 2004;  Bomken et al 2015). 
In patients bearing this association, a significantly 
increased risk of cardiac and vascular thrombosis 
exists, and congestive heart failure represents the 
main cause of mortality in patients with ALL and 
hypereosinophilia (Nie et al, 2010; Parasole et al, 
2014).  Based on the literature review 30% of 
patients died as a result of congestive heart failure 
attributed to the eosinophilia (Fishel et al, 1990). 
Pneumonia or pulmonary infiltrates were present in 
50% and chest pain was reported in 20% of  
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patients. Thrombotic complications may occur in 
this subset of ALL therefore, prompt heparin 
prophylaxis or chemotherapic modulation of 
prothrombotic drugs should be planned. 
Eosinophilic infiltration into endomyocardial, 
pleural and pulmonary tissue has been documented 
in those patients (Parasole et al, 2014). Eosinophilia 
quickly resolved upon achievement of remission, 
but in most patients reappeared during relapse. 
Thus, eosinophilia is an important clinical marker 
to monitor this disease, which disappears with 
chemotherapy whereas its recurrence following 
remission is an indication of relapse of ALL. 
Cytology 
Peripheral blood usually shows leukocytosis and 
marked eosinophilia. The initial white blood cell 
count ranged from 4-148x 109/L with an average 
eosinophilia of 55% and rare circulating blast cells. 
Blasts may be absent in peripheral blood which 
could lead to delay in the diagnosis, if bone marrow 
aspiration is not done (Wilson and Tefferi, 2005; 
D'Angelo et al 2008).  Many of the laboratory 
abnormalities characteristic of hypereosinophilic 
syndrome (HES), including eosinophil dysplasia, 
and elevated B12 levels can also be seen in ALL 
with eosinophilia. Interestingly, elevation of serum 
tryptase, which is associated with imatinib 
responsive HES, has not been reported (Robyn et al 
2004). 
Pathology 
Bone marrow aspirate and biopsy show 
hypercellular marrow infiltrated with blasts, and the 
presence of marked eosinophilia; both precursor 
and normally maturing eosinophils. The blasts have 
typical morphology of lymphoblasts and express B-
precursor phenotypes classically CD19+ and 
CD10+. 
Prognosis 
ALL with eosinophilia is an aggressive form of 
ALL. Prognosis is poor both in children and adults 
(Sutton et al 2008; Wilson et al, 2010). Although 
response to initial chemotherapy was good, relapse 
occurred in most patients. The prognosis of patients 
reviewed by Fishel et al was quite poor; 22 of 24 
patients died within 5 years of diagnosis, with a 
median time from diagnosis to death of 7.5 months. 
Death resulted from either complications of 
chemotherapy or from organ failure secondary to 
overwhelming infiltration by eosinophils. Sutton et 
al described two patients in a cohort of 391 
pediatric ALL (Sutton et al 2008). Both patients 
had a very poor molecular response to initial 
chemotherapy as measured by high minimal 
residual disease (MRD) and were stratified to the 
high-risk group to receive intensive chemotherapy 
followed by bone marrow transplantation. One 
patient had subsequently relapsed and the 
hypereosinophilia, which also recurred, was of 
donor cell origin. 
Cytogenetics 
Note 
Cytogenetic abnormalities are found only in 
leukemic blasts whereas eosinophils have normal 
karyotype indicating not a clonal population.  Based 
on limited reported cases, approximately 2/3 of 
ALL with eosinophilia cases have chromosomal 
abnormalities with the most recurrent being: 
Cytogenetics morphological 
t(5;14)(q31;q32)  this translocation, 
t(5;14)(q31;q32), has been identified in almost 50% 
of cases (Hogan et al, 1987; Grimaldi and Meeker 
1989; Bomken et al, 2015).  The breakpoint of this 
unique translocation has been cloned and shown to 
juxtapose the IGH/14q32 enhancer and IL3/5q31 
gene, resulting in a constitutive expression of IL3 
(Meeker et al, 1990). While IL3 promotes 
production and survival of eosinophils, high serum 
levels of IL3 have been postulated to be responsible 
for the reactive hypereosinophilia. High serum IL3 
levels have been demonstrated in one case at 
diagnosis and seen to recur at leukemic relapse.  
 t(5;9)(q31;p24)  Nuñez et al reported a novel 
t(5;9)(q31;p24), in a patient with B-cell ALL 
associated with eosinophilia. In this case the 
t(5;9)(q31;p24) possibly led to fusion of the 
IL3/5q31  and JAK2/9p24 genes that may explain 
the simultaneous appearance of eosinophilia and 
ALL (Nuñez et al 2003).  
 Other recurrent chromosome abnormalities  
reported in ALL with eosinophilia are deletion of 
5q, deletion of 7q, deletion of 9p21 with biallelic 
deletion of CDKN2A (cyclin dependent kinase 2a / 
p16), t(7;12)(q22;p13) (Wynn et al, 2003; Wilson et 
al, 2005; Rezk et al 2006;  D'Angelo et al, 2008; 
Parasole et al, 2014; Bhatti et al, 2009). These 
chromosomal abnormalities are uncommon in ALL 
without eosinophilia suggesting that this subtype of 
ALL may represent a unique disease entity. 
Genes involved and 
proteins 
IL3 
Location 
5q31.1 
Note 
Alternative symbols: showed that the product of the 
MYC gene has a molecular mass of 65 kD, is 
located predominantly in the nucleus, and binds to 
DNAInterleukin 3; Hematopoietic Growth Factor; 
Multipotential Colony-Stimulating Factor; 
Multilineage-Colony-Stimulating Factor; Colony-
Acute Lymphoblastic Leukemia with Hypereosinophilia Mohamed AN 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2019; 23(2) 51 
 
Stimulating Factor; Multiple; P-Cell Stimulating 
Factor; Mast-Cell Growth Factor. 
Protein 
The protein encoded by IL3 gene is a potent growth 
promoting cytokine. It acts by binding to 
interleukin receptor. This cytokine stimulates the 
proliferation of a broad range of hematopoietic cell 
types. It is involved in a variety of cell activities 
such as cell growth, differentiation and apoptosis. 
JAK2 
Location 
9p24.1 
Protein 
Protein tyrosine kinase of the non-receptor type. 
IGH 
Location 
14q32.33 
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